Medical Cannabis Brands Available in UK Pharmacies: Complete Guide

Medical Cannabis Brands and Products Available in UK Pharmacies

Since legalisation in 2018, the UK medical cannabis market has expanded significantly, offering patients access to a range of brands and products through registered pharmacies. These offerings comprise both domestic producers and internationally recognised companies that have obtained necessary approvals for the UK market. Understanding the available options helps patients and healthcare professionals make informed decisions about treatment pathways.

Grow Pharma: UK-Grown Cannabis

Grow Pharma represents one of the UK’s most significant domestic cannabis cultivation operations. Based in the Midlands, the company has invested heavily in establishing GMP-certified facilities that meet rigorous pharmaceutical standards. Their product range includes whole flower cannabis available in various strain profiles, catering to different therapeutic needs.

Grow Pharma’s offerings feature carefully balanced THC and CBD ratios, ranging from high-CBD, low-THC formulations (such as 1:20 CBD:THC) for patients seeking minimal psychoactive effects, to more balanced ratios (1:1) for those requiring stronger therapeutic action. Their whole flower products are available through UK pharmacies as dispensed medicines, with each product subjected to rigorous testing protocols. UK patients have reported strong confidence in Grow Pharma products, partly due to domestic production transparency and the company’s commitment to pharmaceutical-grade cultivation standards.

Aurora Cannabis: Canadian Excellence

Aurora, one of Canada’s largest cannabis producers, has established a significant presence in the UK market through legal importation agreements. The company operates world-class cultivation facilities in Canada and has expanded internationally to supply medical markets including the UK.

Aurora’s product portfolio includes dried flower, cannabis oils, and capsules with varying cannabinoid profiles. Their formulations typically range from high-CBD products (containing minimal THC) through to balanced and THC-dominant options. Products like their “MedReleaf review” line offer consistent, laboratory-tested cannabinoid ratios that UK patients appreciate for reliability. The brand has cultivated a strong reputation among UK patients seeking internationally sourced, commercially established products with transparent third-party testing.

Khiron: Latin American Innovation

Khiron, headquartered in Colombia, represents a newer entry into the UK medical cannabis market but brings substantial expertise from Latin American cultivation. The company focuses on sustainable, high-quality cannabis production using advanced agricultural techniques suited to optimal growing conditions.

Their UK-available products emphasise whole flower cannabis with carefully controlled cannabinoid profiles. Khiron’s offerings typically feature THC:CBD ratios optimised for specific conditions, with particular strength in high-CBD formulations for patients with seizure disorders or anxiety. UK patient feedback regarding Khiron remains positive, with specific praise for product consistency and competitive pricing, though the brand maintains a smaller market presence compared to established Canadian competitors.

Bedrocan: Dutch Pharmaceutical Tradition

Bedrocan, based in the Netherlands, operates as one of Europe’s oldest and most established medical cannabis producers. The company holds the distinction of being the official supplier for Dutch patients and operates under stringent European pharmaceutical regulations.

Bedrocan’s product range encompasses standardised dried flower preparations with precisely defined THC and CBD content, ranging from their high-THC products (approximately 22% THC, minimal CBD) to high-CBD formulations. Their products undergo rigorous pharmaceutical manufacturing processes, ensuring consistency across batches. UK patients respect Bedrocan’s longstanding reputation and pharmaceutical heritage, though availability through UK pharmacies remains somewhat limited compared to Canadian alternatives.

Tilray and Spectrum Therapeutics

Tilray, a Canada-based company, supplies a comprehensive range of medical cannabis products to UK patients, including dried flower, oils, and capsules. Their formulations span from pure CBD products to balanced ratios and THC-dominant options, each developed with clinical applications in mind.

Spectrum Therapeutics, now operating under Tilray’s ownership, brings additional product sophistication through pharmaceutical-grade oils and standardised formulations. Both brands emphasise clinical research and patient support programmes, earning strong reputations amongst UK practitioners and patients seeking evidence-based treatment options.

Canopy Growth Products

Canopy Growth, another Canadian major producer, offers diverse product formats including whole flower and oil-based formulations. Their UK-available products showcase various cannabinoid ratios tailored to different conditions. The company’s strong research focus and commitment to pharmaceutical standards have generated considerable patient confidence.

Cellen and Little Green Pharma

Cellen, an Italian producer, specialises in high-quality cannabis flower products with emphasis on consistency and purity. Little Green Pharma, from Australia, provides similarly rigorous pharmaceutical-grade products, though UK availability remains more restricted than major Canadian suppliers.

BOA Medical

BOA Medical represents a smaller, specialised producer focusing on particular patient demographics and specific therapeutic applications, with products carefully formulated according to clinical requirements.

UK Pharmacy Distribution: Domestic Versus Imported

UK pharmacies stock both domestically produced cannabis (primarily from Grow Pharma) and legitimately imported products from approved international producers. Imported products undergo stringent importation procedures and must meet UK Medicines and Healthcare products Regulatory Authority standards. Whilst domestic production supports local industry and offers supply security, imported products often provide broader choice in cannabinoid ratios and product formats. Most patients access these products through private prescriptions, though NHS prescribing exists in limited circumstances for specific indications such as treatment-resistant epilepsy, chronic pain, or chemotherapy-related nausea.

The UK medical cannabis market continues evolving, with ongoing discussions about NHS accessibility and expansion of domestic cultivation capacity. Patients should consult healthcare professionals regarding appropriate brand selection based on individual therapeutic requirements and medical history.

Medical Cannabis UK | How to Get a Cannabis Prescription